{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:20:25Z","timestamp":1790659225405,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T00:00:00Z","timestamp":1683158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Emerging evidence supports that dihydroceramides (DhCer) and ceramides (Cer) contribute to the pathophysiology of insulin resistance and liver steatosis, and that their circulating concentrations are independently associated with cardiovascular outcomes. Circulating DhCer levels are increased in patients with type 2 diabetes (T2D). On the other hand, the GLP-1 receptor agonist liraglutide reduces major adverse cardiac events, insulin resistance and liver steatosis in T2D patients. The main purpose of the present study was therefore to investigate whether liraglutide decreases circulating levels of DhCer and Cer in T2D patients, which could be a mechanism involved in its cardiometabolic benefits. The secondary purpose was to assess the relationship between liraglutide-induced changes in DhCer\/Cer levels and insulin resistance and liver steatosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Plasma concentrations of 11 DhCer and 15 Cer species were measured by a highly-sensitive mass spectrometry system in 35 controls and 86 T2D patients before and after 6\u00a0months of liraglutide (1.2\u00a0mg\/day). Insulin resistance was estimated by the triglyceride-glucose (TyG) index. Liver fat content (LFC) was assessed in 53 patients by proton magnetic resonance spectroscopy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Plasma levels of total DhCer, 7 DhCer and 7 Cer species were increased in T2D patients compared to controls. Liraglutide decreased total DhCer by 15.1% (p\u2009=\u20090.005), affecting 16:0 (p\u2009=\u20090.037), 18:0 (p\u2009&lt;\u20090.0001), 18:1 (p\u2009=\u20090.0005), 20:0 (p\u2009=\u20090.0003), 23:0 (p\u2009=\u20090.005) and 24:1 (p\u2009=\u20090.04) species. Total plasma Cer did not significantly change after liraglutide (p\u2009=\u20090.18), but 5\u00a0Cer species decreased significantly, <jats:italic>i.e.<\/jats:italic> 18:0 and 18:1 (both p\u2009&lt;\u20090.0001), 19:0 and 24:1 (both p\u2009&lt;\u20090.01) and 26:1 (p\u2009=\u20090.04). In multivariate analysis, the reduction in DhCer after liraglutide was independently associated with the reduction in LFC (p\u2009=\u20090.0005) and in TyG index (p\u2009=\u20090.05).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Liraglutide reduces plasma levels of numerous DhCer and Cer species in T2D patients, which may contribute to the cardiovascular benefit observed in the LEADER trial. The independent association between the decrease in plasma DhCer level with the reduction in LFC and TyG index adds new insights regarding the relationship between DhCer, liver steatosis and insulin resistance.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic> ClinicalTrials.gov identifier: NCT02721888.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-023-01845-0","type":"journal-article","created":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T09:04:04Z","timestamp":1683191044000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes"],"prefix":"10.1186","volume":"22","clinical-trial-number":[{"clinical-trial-number":"nct02721888","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Damien","family":"Denimal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Bergas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Paul","family":"Pais-de-Barros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Simoneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Demizieux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Passilly-Degrace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Bouillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexia","family":"Rouland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amandine","family":"Bataille","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Duvillard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Verg\u00e8s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,4]]},"reference":[{"issue":"10","key":"1845_CR1","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41569-021-00536-1","volume":"18","author":"RH Choi","year":"2021","unstructured":"Choi RH, Tatum SM, Symons JD, Summers SA, Holland WL. Ceramides and other sphingolipids as drivers of cardiovascular disease. Nat Rev Cardiol. 2021;18(10):701\u201311.","journal-title":"Nat Rev Cardiol"},{"issue":"10","key":"1845_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jlr.2022.100270","volume":"63","author":"S Zarini","year":"2022","unstructured":"Zarini S, Brozinick JT, Zemski Berry KA, Garfield A, Perreault L, Kerege A, et al. Serum dihydroceramides correlate with insulin sensitivity in humans and decrease insulin sensitivity in vitro. J Lipid Res. 2022;63(10): 100270.","journal-title":"J Lipid Res"},{"issue":"2","key":"1845_CR3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2337\/db08-1228","volume":"58","author":"JM Haus","year":"2009","unstructured":"Haus JM, Kashyap SR, Kasumov T, Zhang R, Kelly KR, Defronzo RA, et al. Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance. Diabetes. 2009;58(2):337\u201343.","journal-title":"Diabetes"},{"issue":"13","key":"1845_CR4","first-page":"e126925, 126925","volume":"5","author":"WS Chew","year":"2019","unstructured":"Chew WS, Torta F, Ji S, Choi H, Begum H, Sim X, et al. Large-scale lipidomics identifies associations between plasma sphingolipids and T2DM incidence. JCI Insight. 2019;5(13):e126925, 126925.","journal-title":"JCI Insight"},{"issue":"25","key":"1845_CR5","doi-asserted-by":"publisher","first-page":"1967","DOI":"10.1093\/eurheartj\/ehw148","volume":"37","author":"R Laaksonen","year":"2016","unstructured":"Laaksonen R, Ekroos K, Sysi-Aho M, Hilvo M, Vihervaara T, Kauhanen D, et al. Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. Eur Heart J. 2016;37(25):1967\u201376.","journal-title":"Eur Heart J"},{"issue":"21","key":"1845_CR6","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1161\/CIRCULATIONAHA.116.024261","volume":"135","author":"DD Wang","year":"2017","unstructured":"Wang DD, Toledo E, Hruby A, Rosner BA, Willett WC, Sun Q, et al. Plasma ceramides, mediterranean diet, and incident cardiovascular disease in the PREDIMED trial. Circulation. 2017;135(21):2028\u201340.","journal-title":"Circulation"},{"issue":"3","key":"1845_CR7","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1172\/JCI131838","volume":"130","author":"AM Poss","year":"2020","unstructured":"Poss AM, Maschek JA, Cox JE, Hauner BJ, Hopkins PN, Hunt SC, et al. Machine learning reveals serum sphingolipids as cholesterol-independent biomarkers of coronary artery disease. J Clin Invest. 2020;130(3):1363\u201376.","journal-title":"J Clin Invest"},{"issue":"1","key":"1845_CR8","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1038\/s41467-022-28496-1","volume":"13","author":"C Wittenbecher","year":"2022","unstructured":"Wittenbecher C, Cuadrat R, Johnston L, Eichelmann F, J\u00e4ger S, Kuxhaus O, et al. Dihydroceramide- and ceramide-profiling provides insights into human cardiometabolic disease etiology. Nat Commun. 2022;13(1):936.","journal-title":"Nat Commun"},{"issue":"8","key":"1845_CR9","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/ijo.2012.191","volume":"37","author":"JT Brozinick","year":"2013","unstructured":"Brozinick JT, Hawkins E, Hoang Bui H, Kuo MS, Tan B, Kievit P, et al. Plasma sphingolipids are biomarkers of metabolic syndrome in non-human primates maintained on a Western-style diet. Int J Obes. 2013;37(8):1064\u201370.","journal-title":"Int J Obes"},{"issue":"6","key":"1845_CR10","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.2337\/dc17-1318","volume":"41","author":"M Apostolopoulou","year":"2018","unstructured":"Apostolopoulou M, Gordillo R, Koliaki C, Gancheva S, Jelenik T, De Filippo E, et al. Specific hepatic sphingolipids relate to insulin resistance, oxidative stress, and inflammation in nonalcoholic steatohepatitis. Diabetes Care. 2018;41(6):1235\u201343.","journal-title":"Diabetes Care"},{"issue":"9","key":"1845_CR11","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1016\/j.celrep.2017.02.019","volume":"18","author":"L Wigger","year":"2017","unstructured":"Wigger L, Cruciani-Guglielmacci C, Nicolas A, Denom J, Fernandez N, Fumeron F, et al. Plasma dihydroceramides are diabetes susceptibility biomarker candidates in mice and humans. Cell Rep. 2017;18(9):2269\u201379.","journal-title":"Cell Rep"},{"issue":"4","key":"1845_CR12","doi-asserted-by":"publisher","first-page":"792","DOI":"10.3390\/jcm10040792","volume":"10","author":"E Hajduch","year":"2021","unstructured":"Hajduch E, Lachkar F, Ferr\u00e9 P, Foufelle F. Roles of ceramides in non-alcoholic fatty liver disease. J Clin Med. 2021;10(4):792.","journal-title":"J Clin Med"},{"issue":"7","key":"1845_CR13","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1111\/liv.12331","volume":"34","author":"K Kurek","year":"2014","unstructured":"Kurek K, Piotrowska DM, Wiesio\u0142ek-Kurek P, \u0141ukaszuk B, Chabowski A, G\u00f3rski J, et al. Inhibition of ceramide de novo synthesis reduces liver lipid accumulation in rats with nonalcoholic fatty liver disease. Liver Int. 2014;34(7):1074\u201383.","journal-title":"Liver Int"},{"issue":"3","key":"1845_CR14","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/j.jhep.2021.04.013","volume":"75","author":"GJ Ooi","year":"2021","unstructured":"Ooi GJ, Meikle PJ, Huynh K, Earnest A, Roberts SK, Kemp W, et al. Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis. J Hepatol. 2021;75(3):524\u201335.","journal-title":"J Hepatol"},{"issue":"9","key":"1845_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100154","volume":"1","author":"A Carlier","year":"2020","unstructured":"Carlier A, Phan F, Szpigel A, Hajduch E, Salem JE, Gautheron J, et al. Dihydroceramides in triglyceride-enriched VLDL are associated with nonalcoholic fatty liver disease severity in type 2 diabetes. Cell Rep Med. 2020;1(9): 100154.","journal-title":"Cell Rep Med"},{"issue":"4","key":"1845_CR16","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311\u201322.","journal-title":"N Engl J Med"},{"key":"1845_CR17","doi-asserted-by":"publisher","first-page":"3715026","DOI":"10.1155\/2021\/3715026","volume":"2021","author":"X Li","year":"2021","unstructured":"Li X, Wu X, Jia Y, Fu J, Zhang L, Jiang T, et al. Liraglutide decreases liver fat content and serum fibroblast growth factor 21 levels in newly diagnosed overweight patients with type 2 diabetes and nonalcoholic fatty liver disease. J Diabetes Res. 2021;2021:3715026.","journal-title":"J Diabetes Res"},{"issue":"7","key":"1845_CR18","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.2337\/dc08-2124","volume":"32","author":"B Zinman","year":"2009","unstructured":"Zinman B, Gerich J, Buse JB, Lewin A, Schwartz S, Raskin P, et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care. 2009;32(7):1224\u201330.","journal-title":"Diabetes Care"},{"issue":"9","key":"1845_CR19","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1161\/ATVBAHA.118.310990","volume":"38","author":"B Verg\u00e8s","year":"2018","unstructured":"Verg\u00e8s B, Duvillard L, De Pais BJP, Bouillet B, Baillot-Rudoni S, Rouland A, et al. Liraglutide reduces postprandial hyperlipidemia by increasing apoB48 (apolipoprotein B48) catabolism and by reducing apoB48 production in patients with type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2018;38(9):2198\u2013206.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7","key":"1845_CR20","doi-asserted-by":"publisher","first-page":"876","DOI":"10.3390\/medicina58070876","volume":"58","author":"P Luo","year":"2022","unstructured":"Luo P, Cao Y, Li P, Li W, Song Z, Fu Z, et al. TyG index performs better than HOMA-IR in chinese type 2 diabetes mellitus with a BMI < 35 kg\/m2: a hyperglycemic clamp validated study. Medicina. 2022;58(7):876.","journal-title":"Medicina"},{"issue":"1","key":"1845_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s12933-022-01511-x","volume":"21","author":"LC Tao","year":"2022","unstructured":"Tao LC, Xu J, Wang TT, Hua F, Li JJ. Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations. Cardiovasc Diabetol. 2022;21(1):68.","journal-title":"Cardiovasc Diabetol"},{"issue":"31","key":"1845_CR22","doi-asserted-by":"publisher","first-page":"16328","DOI":"10.1074\/jbc.M115.709626","volume":"291","author":"TTT Tran","year":"2016","unstructured":"Tran TTT, Postal BG, Demignot S, Ribeiro A, Osinski C, de Pais Barros JP, et al. Short term palmitate supply impairs intestinal insulin signaling via ceramide production. J Biol Chem. 2016;291(31):16328\u201338.","journal-title":"J Biol Chem"},{"issue":"2","key":"1845_CR23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s00125-017-4462-5","volume":"61","author":"A Szpigel","year":"2018","unstructured":"Szpigel A, Hainault I, Carlier A, Venteclef N, Batto AF, Hajduch E, et al. Lipid environment induces ER stress, TXNIP expression and inflammation in immune cells of individuals with type 2 diabetes. Diabetologia. 2018;61(2):399\u2013412.","journal-title":"Diabetologia"},{"issue":"9\u201310","key":"1845_CR24","first-page":"995","volume":"26","author":"X Lopez","year":"2013","unstructured":"Lopez X, Goldfine AB, Holland WL, Gordillo R, Scherer PE. Plasma ceramides are elevated in female children and adolescents with type 2 diabetes. J Pediatr Endocrinol Metab. 2013;26(9\u201310):995\u20138.","journal-title":"J Pediatr Endocrinol Metab"},{"key":"1845_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.677202","volume":"13","author":"L Zhang","year":"2022","unstructured":"Zhang L, Hu Y, An Y, Wang Q, Liu J, Wang G. The changes of lipidomic profiles reveal therapeutic effects of exenatide in patients with type 2 diabetes. Front Endocrinol. 2022;13: 677202.","journal-title":"Front Endocrinol"},{"issue":"9683","key":"1845_CR26","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0140-6736(09)60659-0","volume":"374","author":"JB Buse","year":"2009","unstructured":"Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009;374(9683):39\u201347.","journal-title":"Lancet"},{"issue":"1","key":"1845_CR27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s12933-021-01431-2","volume":"20","author":"J Jendle","year":"2021","unstructured":"Jendle J, Hy\u00f6tyl\u00e4inen T, Ore\u0161i\u010d M, Nystr\u00f6m T. Pharmacometabolomic profiles in type 2 diabetic subjects treated with liraglutide or glimepiride. Cardiovasc Diabetol. 2021;20(1):237.","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"1845_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002395","volume":"9","author":"EH Zobel","year":"2021","unstructured":"Zobel EH, Wretlind A, Ripa RS, Rotbain Curovic V, von Scholten BJ, Suvitaival T, et al. Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial. BMJ Open Diabetes Res Care. 2021;9(1): e002395.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"12","key":"1845_CR29","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1161\/ATVBAHA.116.307497","volume":"36","author":"AS Havulinna","year":"2016","unstructured":"Havulinna AS, Sysi-Aho M, Hilvo M, Kauhanen D, Hurme R, Ekroos K, et al. Circulating ceramides predict cardiovascular outcomes in the population-based FINRISK 2002 cohort. Arterioscler Thromb Vasc Biol. 2016;36(12):2424\u201330.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"21","key":"1845_CR30","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1161\/CIRCULATIONAHA.116.023233","volume":"134","author":"ZH Alshehry","year":"2016","unstructured":"Alshehry ZH, Mundra PA, Barlow CK, Mellett NA, Wong G, McConville MJ, et al. Plasma lipidomic profiles improve on traditional risk factors for the prediction of cardiovascular events in type 2 diabetes mellitus. Circulation. 2016;134(21):1637\u201350.","journal-title":"Circulation"},{"key":"1845_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.trsl.2020.07.008","volume":"227","author":"E Somm","year":"2021","unstructured":"Somm E, Montandon SA, Loizides-Mangold U, Ga\u00efa N, Lazarevic V, De Vito C, et al. The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet. Transl Res. 2021;227:75\u201388.","journal-title":"Transl Res"},{"issue":"11","key":"1845_CR32","doi-asserted-by":"publisher","first-page":"4136","DOI":"10.1210\/jc.2017-00970","volume":"102","author":"A Leonardini","year":"2017","unstructured":"Leonardini A, D\u2019Oria R, Incalza MA, Caccioppoli C, Andrulli Buccheri V, Cignarelli A, et al. GLP-1 receptor activation inhibits palmitate-induced apoptosis via ceramide in human cardiac progenitor cells. J Clin Endocrinol Metab. 2017;102(11):4136\u201347.","journal-title":"J Clin Endocrinol Metab"},{"key":"1845_CR33","doi-asserted-by":"publisher","first-page":"e706416","DOI":"10.1155\/2015\/706416","volume":"2015","author":"H Jinnouchi","year":"2015","unstructured":"Jinnouchi H, Sugiyama S, Yoshida A, Hieshima K, Kurinami N, Suzuki T, et al. Liraglutide, a glucagon-like peptide-1 analog, increased insulin sensitivity assessed by hyperinsulinemic-euglycemic clamp examination in patients with uncontrolled type 2 diabetes mellitus. J Diabetes Res. 2015;2015:e706416.","journal-title":"J Diabetes Res"},{"issue":"3\u20134","key":"1845_CR34","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.bbrc.2017.10.110","volume":"494","author":"AY Lee","year":"2017","unstructured":"Lee AY, Lee JW, Kim JE, Mock HJ, Park S, Kim S, et al. Dihydroceramide is a key metabolite that regulates autophagy and promotes fibrosis in hepatic steatosis model. Biochem Biophys Res Commun. 2017;494(3\u20134):460\u20139.","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01845-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-023-01845-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-023-01845-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,4]],"date-time":"2023-05-04T09:08:07Z","timestamp":1683191287000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-023-01845-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,4]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1845"],"URL":"https:\/\/doi.org\/10.1186\/s12933-023-01845-0","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,4]]},"assertion":[{"value":"23 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study complies with the Declaration of Helsinki and was approved by the our regional ethics committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors\u2019 employer (University Hospital of Dijon, France) received funding from Novo Nordisk for this study. Novo Nordisk had no role in collection, analysis, and interpretation of data, in writing the paper, and in the decision to submit the paper for publication. Otherwise, no potential competing interests relevant to this article are reported.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}